Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GPO safety zone

This article was originally published in The Gray Sheet

Executive Summary

Group purchasing organizations participating in anti-competitive contracting practices should be disqualified from the Healthcare Policy Statement 7 antitrust safety zone, Sen. Herb Kohl (D-Wisc.) recommends in an Oct. 23 letter to FTC and DoJ. Disparate product bundling, sole-source contracting and practices that stifle innovation are cited as examples of excludable actions. Coming on the heels of a Sept. 26 FTC/DoJ hearing on GPOs, the missive also suggests decreasing the 35% market share threshold sanctioned by the safety zone (1"The Gray Sheet" Oct. 13, 2003, p. 5)...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT019222

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel